Multicenter, randomized, double‐blind, controlled trial of treatment of active rheumatoid arthritis with T‐614 compared with methotrexate
Arthritis Care & Research2009Vol. 61(7), pp. 979–987
Citations Over TimeTop 23% of 2009 papers
Liangjing Lu, Chunde Bao, Min Dai, Jialin Teng, Wei Fan, Fang Du, Nan‐ping Yang, Y.-K. Zhao, Zhi‐wei Chen, Kang Xu, Peigen He, Huaxiang Wu, Tao Yi, M. Zhang, Xing-hai HAN, Xing‐Fu Li, Jieruo Gu, Jianhua Li, Hao Yu
Abstract
Results indicate that T-614 therapy 50 mg/day is effective and well tolerated, and represents a new option for the treatment of patients with active RA.
Related Papers
- → Statistical issues relating to international differences in clinical trials(2001)27 cited
- → Single-center versus multicenter trials(1986)13 cited
- → Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis(2012)1 cited
- → German Multicenter Studies on Plateletpheresis from Healthy Donors(1993)1 cited
- Efficacy and Safety of virtual reality in Stroke Rehabilitation: a multicenter randomized trial (EVREST Multicenter)(2016)